SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SEGALA, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.982
AS - Asia 4.188
EU - Europa 3.847
SA - Sud America 771
AF - Africa 87
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 6
Totale 15.895
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.777
SG - Singapore 1.812
IT - Italia 1.418
CN - Cina 1.123
PL - Polonia 759
BR - Brasile 660
DE - Germania 529
HK - Hong Kong 516
VN - Vietnam 269
GB - Regno Unito 226
FI - Finlandia 178
RU - Federazione Russa 148
ID - Indonesia 131
UA - Ucraina 131
SE - Svezia 121
MX - Messico 95
CA - Canada 91
TR - Turchia 86
FR - Francia 74
IN - India 73
NL - Olanda 70
AT - Austria 46
AR - Argentina 43
BD - Bangladesh 42
ZA - Sudafrica 35
ES - Italia 32
JP - Giappone 29
LT - Lituania 28
BE - Belgio 25
EC - Ecuador 16
IQ - Iraq 16
CO - Colombia 13
CZ - Repubblica Ceca 13
KE - Kenya 12
CL - Cile 11
IE - Irlanda 11
MA - Marocco 11
TH - Thailandia 10
AU - Australia 9
CH - Svizzera 9
CM - Camerun 9
PY - Paraguay 9
KR - Corea 8
PE - Perù 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
EG - Egitto 7
UZ - Uzbekistan 7
IL - Israele 6
VE - Venezuela 6
EU - Europa 5
MY - Malesia 5
TN - Tunisia 5
AL - Albania 4
BG - Bulgaria 4
KZ - Kazakistan 4
NO - Norvegia 4
PH - Filippine 4
SA - Arabia Saudita 4
AZ - Azerbaigian 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
GE - Georgia 3
HN - Honduras 3
IR - Iran 3
JM - Giamaica 3
OM - Oman 3
RS - Serbia 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
GT - Guatemala 2
JO - Giordania 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
SR - Suriname 2
UY - Uruguay 2
AP - ???statistics.table.value.countryCode.AP??? 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CV - Capo Verde 1
DM - Dominica 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
KG - Kirghizistan 1
KI - Kiribati 1
MK - Macedonia 1
PT - Portogallo 1
QA - Qatar 1
RE - Reunion 1
RO - Romania 1
Totale 15.887
Salva come PNG Salva come JPEG
Città #
Ashburn 1.047
Singapore 902
Warsaw 753
Beijing 613
Fairfield 588
Santa Clara 580
Hong Kong 515
Chandler 348
Woodbridge 309
Houston 247
Munich 247
Wilmington 237
Seattle 230
Cambridge 176
Los Angeles 165
Princeton 154
Dallas 139
Ferrara 137
Jakarta 115
Ann Arbor 111
Jacksonville 103
Milan 103
Ho Chi Minh City 91
New York 90
Helsinki 86
Rome 78
Mexico City 73
Dong Ket 69
Shanghai 69
San Diego 68
Turku 64
London 63
Bremen 59
São Paulo 59
Nuremberg 55
Bologna 53
Izmir 47
Brooklyn 44
Washington 43
Chicago 40
Hanoi 40
Boardman 39
Falls Church 37
Nanjing 37
Frankfurt am Main 33
Redwood City 31
Stockholm 30
Verona 30
Tokyo 28
Boston 27
Buffalo 27
Dearborn 27
Falkenstein 27
Addison 26
Denver 26
Johannesburg 26
Chennai 25
San Francisco 25
Toronto 25
Atlanta 24
Montreal 24
Moscow 24
Rio de Janeiro 24
Brussels 23
Santa Maria Di Sala 22
Hefei 20
Phoenix 20
The Dalles 20
Tianjin 20
Amsterdam 19
Orem 19
Poplar 18
Vienna 18
Belo Horizonte 17
Naples 16
Manchester 15
Mountain View 15
Norwalk 15
San Mateo 15
Charlotte 14
Council Bluffs 14
Padova 14
Ankara 12
Brasília 11
Portsmouth 11
Augusta 10
Nairobi 10
Nanchang 10
Shenyang 10
Birmingham 9
Columbus 9
Da Nang 9
Fortaleza 9
Lappeenranta 9
Lauterbourg 9
Palermo 9
Porto Alegre 9
Curitiba 8
Dhaka 8
Goiânia 8
Totale 10.136
Salva come PNG Salva come JPEG
Nome #
Endocardite da Bartonella henselae? Riscontro di anticorpi anti-fosfolipidi, anti-beta2-glicoproteina e anti-cardiolipina. 662
Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program 304
INTERVENTO DI FORMAZIONE/INFORMAZIONE CIRCA LE MODALITÀ DI TRASMISSIONE/PREVENZIONE DI MALATTIE SESSUALMENTE TRASMISSIBILI (SDTS) AD UNA POPOLAZIONE DI MIGRANTI RICHIEDENTI ASILO/RIFUGIATI CON OFFERTA ATTIVA DEL TEST HIV. STUDIO PILOTA NELLA PROVINCIA DI FERRARA. DATI PRELIMINARI 231
INDAGINE RETROSPETTIVA DELLE LINFOADENOPATIE INFETTIVE. RUOLO DEI TESTS MOLECOLARI. 194
Proportion of PLWH not vaccinated for COVID-19 in Italy and predictors 186
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 186
INFEZIONI DEL SISTEMA NERVOSO CENTRALE E CHLAMYDIA PNEUMONIAE. RUOLO ETIOPATOGENETICO NELLA SCLEROSI MULTIPLA 182
Investigation of Chlamydia pneumonite and Mycoplasma spp. In clinical specimens from patients with arhritis 168
Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses 151
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 150
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS 148
Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area. 147
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 147
EPATITE CRONICA C E SINDROME DI EHLERS DANLOS (EDS). 145
Approccio multidisciplinare per il trattamento delle osteomieliti croniche e delle infezioni di dispositivi ortopedici. Risultati Preliminari 145
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 144
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 141
Recovery of Enterococcus gallinarum in patients with infected cardiac pacemaker pockets. 140
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 138
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study 136
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection 134
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 132
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV 130
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 130
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 129
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 128
RISPOSTA VIROLOGICA SOSTENUTA DOPO TRATTAMENTO BREVE CON DI PEGINTERFERON ALFA-2A E RIBAVIRINA IN CORSO DI EPATITE CRONICA DA HCV 127
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 126
Factors that influence HCV related liver disease severity in Italian patients in care: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti ViRali) HCV cohort study". 126
Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation 125
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality 125
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 123
Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice 122
Implicazioni diagnostiche e terapeutiche in un paziente con Infezione da Parvovirus B-19 e sarcoidosi 121
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 118
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 117
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 117
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 117
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study Disease epidemiology - Infectious 116
Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART 116
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 116
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 116
Atazanavir/rit(atz/r),unboosted atazanavir (atz) or darunavir/rit(drv/r):metabolic safety and liver fibrosis in hiv/hcv coinfected patients (master cohort) 116
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort 115
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 114
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice 114
ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI 113
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 111
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 111
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 109
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 108
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 108
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 107
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 107
EVALUATION OF THE SWITCH TO A DUAL ART REGIMEN WITH LAMIVUDINE PLUS DOLUTEGRAVIR OR PROTEASE INHIBITORS IN HIV-INFECTED VIROLOGICALLY SUPPRESSED PATIENTS. A REAL LIFE EXPERIENCE 106
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 106
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 106
null 106
Limited occurence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study 106
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 105
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 104
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 104
Three-years follow up of raltegravir and/or maraviroc-based regimens in patients experienced to PI, NRTI, NNRTI. Update from the ISS-NIA cohort 103
Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome 103
Broncopolmonite con empieva pleurico da Streptococcus pluranimalium in paziente tossicodipendente: considerazioni clinico-epidemiologiche. 102
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 101
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 100
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 100
CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period. 99
Multidrug Resistant Bacterial Co-Infections in Critically Ill Patients with COVID-19: A Review after Three Years of Pandemic 98
PITER-HCV cohort study as part of the Italian platform for the study of viral hepatitis therapies 98
Associations between immune depression and cardiovascular events in HIV infection 98
Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings 98
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 96
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 96
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 96
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: Data from the ICONA foundation study group, years 1997-2013 96
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 94
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D Study a 93
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 93
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 92
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 92
Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy 92
Antiretroviral Therapy Partially Restores Phenotypic and Metabolic Immunosenescence Features of T Cells in Hiv Infected Individuals 91
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 91
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 91
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 91
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 90
Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectivness And Impact on Liver Fibrosis (MASTER Cohort) 90
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 90
Time to undetectable viral load achievement after art start and risk of mortality. 89
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 87
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 86
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens 85
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 85
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 84
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 84
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 83
Serious liver events and liver-related deaths in HIV/HCV co-infected patients with diabetes: data from the ICONA Foundation Cohort Study. 83
La applicazione delle Linee Guida Italiane di terapia antiretrovirale nella realtà ambulatoriale: efficacia e tollerabilità della cART di prima linea. 83
Totale 12.255
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.634
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.976
Totale 100.610
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.723 0 0 0 0 301 303 224 211 124 310 89 161
2021/20221.086 74 96 23 15 57 89 56 65 38 121 53 399
2022/2023988 158 65 66 54 173 92 52 95 117 12 71 33
2023/20241.102 55 100 82 41 115 223 27 74 34 29 37 285
2024/20254.195 101 88 350 163 469 482 155 167 683 550 540 447
2025/20264.382 1.035 396 811 1.120 1.020 0 0 0 0 0 0 0
Totale 16.298